Prognostic value of type 2 diabetes mellitus and visfatin level in patients after coronary artery bypass grafting

Objective — Our study aimed to evaluate the prognostic value of type 2 diabetes mellitus (DM) and the level of visfatin in patients undergoing coronary artery bypass grafting (CABG). Methods — Our study included 103 patients with chronic heart failure and stable coronary artery disease. The clinica...

Full description

Saved in:
Bibliographic Details
Main Authors: Alla A. Garganeeva, Elena A. Kuzheleva, Olga V. Tukish, Sergey L. Andreev, Oksana N. Ogurkova, Sergey V. Popov
Format: Article
Language:English
Published: Limited liability company «Science and Innovations» (Saratov) 2023-06-01
Series:Russian Open Medical Journal
Subjects:
Online Access:https://romj.org/node/526
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849697141083078656
author Alla A. Garganeeva
Elena A. Kuzheleva
Olga V. Tukish
Sergey L. Andreev
Oksana N. Ogurkova
Sergey V. Popov
author_facet Alla A. Garganeeva
Elena A. Kuzheleva
Olga V. Tukish
Sergey L. Andreev
Oksana N. Ogurkova
Sergey V. Popov
author_sort Alla A. Garganeeva
collection DOAJ
description Objective — Our study aimed to evaluate the prognostic value of type 2 diabetes mellitus (DM) and the level of visfatin in patients undergoing coronary artery bypass grafting (CABG). Methods — Our study included 103 patients with chronic heart failure and stable coronary artery disease. The clinical outcomes and adverse cardiovascular events were analyzed 12 months after the CABG. Results — The patients were distributed between two groups: Group 1 (without registration of composite endpoints, n=71) and Group 2 (patients with the development of composite endpoints, n=32). In Group 1, 22.5% of patients were diagnosed with DM vs. 31.2% in Group 2 (p=0.346). Kaplan-Meier estimator demonstrated that patients with duration of DM over 5 years experienced significantly earlier and more frequent adverse cardiovascular events after CABG vs. patients without DM or with duration of DM less than 5 years. The visfatin level before CABG did not differ between the groups (p=0.416), whereas 10 days after CABG it was higher in Group 2. Correlation between the difference in visfatin levels before and after CABG and duration of type 2 DM was calculated (r=0.54, p=0.041). Conclusion — In patients after CABG, the duration of DM had a negative impact on the development of cardiovascular events. With a duration of DM exceeding 5 years, the risk of adverse events increased significantly. An increase in visfatin level 10 days after CABG was associated with the duration of DM and the development of adverse cardiovascular events in patients.
format Article
id doaj-art-298a5a9d77ef46fa9ebfd82d4b84e6ec
institution DOAJ
issn 2304-3415
language English
publishDate 2023-06-01
publisher Limited liability company «Science and Innovations» (Saratov)
record_format Article
series Russian Open Medical Journal
spelling doaj-art-298a5a9d77ef46fa9ebfd82d4b84e6ec2025-08-20T03:19:17ZengLimited liability company «Science and Innovations» (Saratov)Russian Open Medical Journal2304-34152023-06-01122e020510.15275/rusomj.2023.0205Prognostic value of type 2 diabetes mellitus and visfatin level in patients after coronary artery bypass graftingAlla A. GarganeevaElena A. KuzhelevaOlga V. TukishSergey L. AndreevOksana N. OgurkovaSergey V. PopovObjective — Our study aimed to evaluate the prognostic value of type 2 diabetes mellitus (DM) and the level of visfatin in patients undergoing coronary artery bypass grafting (CABG). Methods — Our study included 103 patients with chronic heart failure and stable coronary artery disease. The clinical outcomes and adverse cardiovascular events were analyzed 12 months after the CABG. Results — The patients were distributed between two groups: Group 1 (without registration of composite endpoints, n=71) and Group 2 (patients with the development of composite endpoints, n=32). In Group 1, 22.5% of patients were diagnosed with DM vs. 31.2% in Group 2 (p=0.346). Kaplan-Meier estimator demonstrated that patients with duration of DM over 5 years experienced significantly earlier and more frequent adverse cardiovascular events after CABG vs. patients without DM or with duration of DM less than 5 years. The visfatin level before CABG did not differ between the groups (p=0.416), whereas 10 days after CABG it was higher in Group 2. Correlation between the difference in visfatin levels before and after CABG and duration of type 2 DM was calculated (r=0.54, p=0.041). Conclusion — In patients after CABG, the duration of DM had a negative impact on the development of cardiovascular events. With a duration of DM exceeding 5 years, the risk of adverse events increased significantly. An increase in visfatin level 10 days after CABG was associated with the duration of DM and the development of adverse cardiovascular events in patients.https://romj.org/node/526diabetes mellituscoronary artery diseaseheart failurecoronary artery bypass graftingvisfatin
spellingShingle Alla A. Garganeeva
Elena A. Kuzheleva
Olga V. Tukish
Sergey L. Andreev
Oksana N. Ogurkova
Sergey V. Popov
Prognostic value of type 2 diabetes mellitus and visfatin level in patients after coronary artery bypass grafting
Russian Open Medical Journal
diabetes mellitus
coronary artery disease
heart failure
coronary artery bypass grafting
visfatin
title Prognostic value of type 2 diabetes mellitus and visfatin level in patients after coronary artery bypass grafting
title_full Prognostic value of type 2 diabetes mellitus and visfatin level in patients after coronary artery bypass grafting
title_fullStr Prognostic value of type 2 diabetes mellitus and visfatin level in patients after coronary artery bypass grafting
title_full_unstemmed Prognostic value of type 2 diabetes mellitus and visfatin level in patients after coronary artery bypass grafting
title_short Prognostic value of type 2 diabetes mellitus and visfatin level in patients after coronary artery bypass grafting
title_sort prognostic value of type 2 diabetes mellitus and visfatin level in patients after coronary artery bypass grafting
topic diabetes mellitus
coronary artery disease
heart failure
coronary artery bypass grafting
visfatin
url https://romj.org/node/526
work_keys_str_mv AT allaagarganeeva prognosticvalueoftype2diabetesmellitusandvisfatinlevelinpatientsaftercoronaryarterybypassgrafting
AT elenaakuzheleva prognosticvalueoftype2diabetesmellitusandvisfatinlevelinpatientsaftercoronaryarterybypassgrafting
AT olgavtukish prognosticvalueoftype2diabetesmellitusandvisfatinlevelinpatientsaftercoronaryarterybypassgrafting
AT sergeylandreev prognosticvalueoftype2diabetesmellitusandvisfatinlevelinpatientsaftercoronaryarterybypassgrafting
AT oksananogurkova prognosticvalueoftype2diabetesmellitusandvisfatinlevelinpatientsaftercoronaryarterybypassgrafting
AT sergeyvpopov prognosticvalueoftype2diabetesmellitusandvisfatinlevelinpatientsaftercoronaryarterybypassgrafting